Insider Trading Review: AcelRx Pharmaceuticals, Inc. $ACRX

4a15835145fc3ba9e78fc0970317c07d

AcelRx Pharmaceuticals, Inc. (ACRX) insider have most recently took part in a trading activity. On Aug 24, 2017 Edwards Mark G, Director bought 5,000 shares having total worth of $15,100 at the price of $3.02 per share, following the transaction a total of 120,000 shares owned by Edwards Mark G.

The stock has experienced a total of 2 insider trades in the past three months. These trades include 1 sell activities and 1 buy trades. Furthermore, over the past 12 months , the stock was traded 4 times by insiders. In 3 of these trades, the insider was a seller while an employee of the company was the buyer in 1 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 1 1 9.09%
12 Month 1 3 -16.2%

Shares of AcelRx Pharmaceuticals, Inc. (ACRX) traded up 1.69% on Aug 23, 2017, hitting $3. 797,195 shares of the company’s stock traded hands. AcelRx Pharmaceuticals, Inc. has a 52 week low of $2.05 and a 52 week high of $3.9. The company’s market cap is $174 million.

AcelRx Pharmaceuticals, Inc. (ACRX) last announced its earnings results on Aug 1, 2017. The company reported -0.29 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.27 by $0.02. The company had revenue of $3 million for the quarter, compared to the consensus estimate of $2 million. During the same quarter in the previous year, the company posted -0.24 earnings per share. The company’s revenue for the quarter was down 41% on a year-over-year basis.

2017-08-01 2017-05-08 2017-03-02 2016-11-01 2016-07-28 2016-05-02 2016-03-07 2015-10-29 2015-08-03 2015-05-04
earnings per share -0.29 -0.34 -0.21 -0.25 -0.24 -0.25 -0.24 0.11 -0.20 -0.27
Revenue(M) 2.66 3.11 6.44 3.37 4.53 3.03 1.73 15.43 1.92 0.18

Acelrx Pharmaceuticals Inc. is a specialty pharmaceutical company involved in the development and commercialization of therapies for the treatment of acute and breakthrough pain.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.